Loss of LKB1 disrupts breast epithelial cell polarity and promotes breast cancer metastasis and invasion

Journal of Experimental & Clinical Cancer Research

Peijun Liu²  Jin Yang¹  Wenjie Li²  Xiaona Mao²  Pingping Li²  Jie Liu²  Juan Li² 

[1] Department of Oncology, The First Affiliated Hospital, Xian Jiaotong University College of Medicine, 277 West Yanta Road, Xi¿an 710061, Shaanxi, People¿s Republic of China;Center for Translational Medicine, The First Affiliated Hospital, Xian Jiaotong University College of Medicine, 277 West Yanta Road, Xi¿an 710061, Shaanxi, People¿s Republic of China

关键词: Invasion;    Metastasis;    Cell polarity;    Breast cancer;    LKB1;   

Others  :  1161152
DOI  :  10.1186/s13046-014-0070-0

 received in 2014-04-21, accepted in 2014-08-18,  发布年份 2014

【 摘 要 】

Background

LKB1, also known as STK11, is a master kinase that serves as an energy metabolic sensor and is involved in cell polarity regulation. Recent studies have indicated that LKB1 is related to breast tumorigenesis and breast cancer progression. However, little work has been done on the roles of LKB1 in cell polarity and epithelial-mesenchymal transition in breast cancer. In this study, we tried to prove that loss of LKB1 disrupts breast epithelial cell polarity and causes tumor metastasis and invasion.

Methods

The relationships of LKB1 expression to clinic-pathological parameters and epithelial markers E-cadherin and high-molecular-weight -cytokeratin (HMW-CK) were investigated in 80 clinical breast cancer tissue samples and their paired normal control breast tissue samples by using immunohistochemistry. Then, the LKB1 expressions in metastatic and non-metastatic breast cancer cell lines were compared. The roles of LKB1 in cell polarity and epithelial-mesenchymal transition in breast cancer were determined by using immunofluorescence, western blot assay, and cell migration and invasive assays. Finally, the non-transformed human breast cell line MCF-10A was cultured in three dimensions to further reveal the role of LKB1 in breast epithelial cell polarity maintenance.

Results

Histopathological analysis showed that LKB1 expression level was significantly negatively correlated with breast cancer TNM stage, and positively correlated with ER/PR status and expression levels of E-cadherin and HMW-CK. Immunofluorescence staining showed that LKB1 was co-localized with E-cadherin at adheren junctions. In vitro analysis revealed that loss of LKB1 expression enhanced migration, invasion and the acquisition of mesenchymal phenotype, while LKB1 overexpression in MDA-MB-435 s cells, which have a low basal level of LKB1 expression, promoted the acquisition of epithelial phenotype. Finally, it was found for the first time that endogenous LKB1 knockdown resulted in abnormal cell polarity in acini formed by non-transformed breast epithelial cells grown in 3D culture.

Conclusion

Our data indicated that low expression of LKB1 was significantly associated with established markers of unfavorable breast cancer prognosis, such as loss of ER/PR, E-cadherin and HMW-CK. Knockdown of endogenous LKB1 gave rise to dysregulation of cell polarity and invasive phenotype of breast cancer cells.

【 授权许可】

   
2014 Li et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Jansen M, Ten Klooster JP, Offerhaus GJ, Clevers H: LKB1 and AMPK family signaling: the intimate link between cell polarity and energy metabolism. Physiol Rev 2009, 89(3):777-798.
• [2]Hemminki A: The molecular basis and clinical aspects of Peutz-Jeghers syndrome. Cel and Mol Life Sci 1999, 55(5):735-750.
• [3]Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S: The protein kinase complement of the human genome. Science 2002, 298(5600):1912-1934.
• [4]Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ: AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008, 30(2):214-226.
• [5]Granot Z, Swisa A, Magenheim J, Stolovich-Rain M, Fujimoto W, Manduchi E, Miki T, Lennerz JK, Stoeckert CJ Jr, Meyuhas O, Seino S, Permutt MA, Piwnica-Worms H, Bardeesy N, Dor Y: LKB1 regulates pancreatic beta cell size, polarity, and function. Cell Met 2009, 10(4):296-308.
• [6]Spicer J, Ashworth A: LKB1 kinase: master and commander of metabolism and polarity. Cur Biol 2004, 14(10):383-395.
• [7]Hardie DG: AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007, 8(10):774-785.
• [8]Wodarz A: Establishing cell polarity in development. Nat Cell Biol 2002, 4(2):39-44.
• [9]Mirouse V, Billaud M: The LKB1/AMPK polarity pathway. FEBS Lett 2011, 585(7):981-985.
• [10]Watts JL, Morton DG, Bestman J, Kemphues KJ: The C. elegans par-4 gene encodes a putative serine-threonine kinase required for establishing embryonic asymmetry. Development 2000, 127(7):1467-1475.
• [11]Bonaccorsi S, Mottier V, Giansanti MG, Bolkan BJ, Williams B, Goldberg ML, Gatti M: The Drosophila Lkb1 kinase is required for spindle formation and asymmetric neuroblast division. Development 2007, 134(11):2183-2193.
• [12]Barnes AP, Lilley BN, Pan YA, Plummer LJ, Powell AW, Raines AN, Sanes JR, Polleux F: LKB1 and SAD kinases define a pathway required for the polarization of cortical neurons. Cell 2007, 129(3):549-563.
• [13]Hezel AF, Gurumurthy S, Granot Z, Swisa A, Chu GC, Bailey G, Dor Y, Bardeesy N, DePinho RA: Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms. Mol and Cel Biol 2008, 28(7):2414-2425.
• [14]Shelly M, Poo MM: Role of LKB1-SAD/MARK pathway in neuronal polarization. Dev Neuro 2011, 71(6):508-527.
• [15]Baas AF, Kuipers J, van der Wel NN, Batlle E, Koerten HK, Peters PJ, Clevers HC: Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD. Cell 2004, 116(3):457-466.
• [16]Baas A, Boudeau J, Sapkota G, Smit L, Medema R, Morrice N, Alessi D, Clevers H: Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. The EMBO journal 2003, 22(12):3062-3072.
• [17]Göransson O, Deak M, Wullschleger S, Morrice NA, Alan RP, Alessi DR: Regulation of the polarity kinases PAR-1/MARK by 14¿3¿3 interaction and phosphorylation. J Cell Sci 2006, 119(19):4059-4070.
• [18]Roy BC, Kohno T, Iwakawa R, Moriguchi T, Kiyono T, Morishita K, Sanchez-Cespedes M, Akiyama T, Yokota J: Involvement of LKB1 in epithelial-mesenchymal transition (EMT) of human lung cancer cells. Lung Cancer 2010, 70(2):136-145.
• [19]Etienne-Manneville S: Polarity proteins in migration and invasion. Oncogene 2008, 27(55):6970-6980.
• [20]Martin-Belmonte F, Perez-Moreno M: Epithelial cell polarity, stem cells and cancer. Nat Rev Cancer 2012, 12(1):23-38.
• [21]Zhuang ZG, Di GH, Shen ZZ, Ding J, Shao ZM: Enhanced expression of LKB1 in breast cancer cells attenuates angiogenesis, invasion, and metastatic potential. Mol Cancer Res 2006, 4(11):843-849.
• [22]Zeisberg M, Neilson EG: Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009, 119(6):1429-1437.
• [23]Manna AK, Pathak S, Gayen P, Sarkar DK, Kundu AK: Study of immunohistochemistry in prostatic lesions with special reference to proliferation and invasiveness. Indian J Surg 2011, 73(2):101-106.
• [24]Sebbagh M, Santoni MJ, Hall B, Borg JP, Schwartz MA: Regulation of LKB1/STRAD localization and function by E-cadherin. Curr Biol 2009, 19(1):37-42.
• [25]Lee JM, Dedhar S, Kalluri R, Thompson EW: The epithelial¿mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006, 172(7):973-981.
• [26]Acloque H, Thiery JP, Nieto MA: The physiology and pathology of the EMT. EMBO Rep 2008, 9(4):322-326.
• [27]Mu ZM, Li H, Fernandez SV, Alpaugh KR, Zhang RG, Massimo CF: EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells. J Exp Clin Cancer Res 2013, 32(70):6.
• [28]Li HD, Luo JS, Liang J, Zhao S, Su RJ: Knockdown of glucose-regulated protein 78 decreases the invasion, metalloproteinase expression and ECM degradation in hepatocellular carcinoma cells. J Exp Clin Cancer Res 2012, 31(39):12. BioMed Central Full Text
• [29]Imbalzano KM, Tatarkova I, Imbalzano AN, Nickerson JA: Increasingly transformed MCF-10A cells have a progressively tumor-like phenotype in three-dimensional basement membrane culture. Cancer Cell Int 2009, 9(7):1-11.
• [30]Partanen JI, Nieminen AI, Klefstrom J: 3D view to tumor suppression: Lkb1, polarity and the arrest of oncogenic c-Myc. Cell Cycle 2009, 8(5):716-724.
• [31]Roy E, Bruyere J, Flamant P, Bigou S, Ausseil J, Vitry S, Heard JM: GM130 gain-of-function induces cell pathology in a model of lysosomal storage disease. Hum Mol Genet 2012, 21(7):1481-1495.
• [32]Nakamura N: Emerging New roles of GM130, a cis-Golgi matrix protein, in higher order cell functions. J Pharmacol Sci 2010, 112(3):255-264.
• [33]Shen Z, Wen XF, Lan F, Shen ZZ, Shao ZM: The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma. Clin Cancer Res 2002, 8(7):2085-2090.
• [34]Marcus AI, Zhou W: LKB1 regulated pathways in lung cancer invasion and metastasis. J Thorac Oncol 2010, 5(12):1883-1886.
• [35]Herrmann JL, Byekova Y, Elmets CA, Athar M: The role of LKB1 in the pathogenesis of skin and other epithelial cancers. Cancer Lett 2011, 306(1):1-9.
• [36]Nath-Sain S, Marignani PA: LKB1 catalytic activity contributes to estrogen receptor alpha signaling. Mol Biol Cell 2009, 20(11):2785-2795.
• [37]Linher-Melville K, Zantinge S, Singh G: Liver kinase B1 expression (LKB1) is repressed by estrogen receptor alpha (ERalpha) in MCF-7 human breast cancer cells. Biochem Biophys Res Commun 2012, 417(3):1063-1068.
• [38]Joensuu K, Leidenius M, Kero M, Andersson LC, Horwitz KB, Heikkila P: ER, PR, HER2, Ki-67 and CK5 in early and late relapsing breast cancer-reduced CK5 expression in metastases. Breast cancer 2013, 7:23-34.
• [39]Choccalingam C, Rao L, Rao S: Clinico-pathological characteristics of triple negative and Non triple negative high grade breast carcinomas with and without basal marker (CK5/6 and EGFR) expression at a rural tertiary hospital in India. Breast cancer 2012, 6:21-29.
• [40]Partanen JI, Nieminen AI, Mäkelä TP, Klefstrom J: Suppression of oncogenic properties of c-Myc by LKB1-controlled epithelial organization. Proc Natl Acad Sci 2007, 104(37):14694-14699.
• [41]Suzuki A, Hirata M, Kamimura K, Maniwa R, Yamanaka T, Mizuno K, Kishikawa M, Hirose H, Amano Y, Izumi N, Miwa Y, Ohno S: aPKC acts upstream of PAR-1b in both the establishment and maintenance of mammalian epithelial polarity. Curr Biol 2004, 14(16):1425-1435.
• [42]Lizcano JM, Goransson O, Toth R, Deak M, Morrice NA, Boudeau J, Hawley SA, Udd L, Makela TP, Hardie DG, Alessi DR: LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 2004, 23(4):833-843.
• [43]Narbonne P, Roy R: Inhibition of germline proliferation during C. elegans dauer development requires PTEN, LKB1 and AMPK signalling. Development 2006, 133(4):611-619.